Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC)

被引：0
|
作者：
Hoff, Camilla Oliveira
McGrail, Daniel
Heeke, Simon
de Sousa, Luana Guimaraes
Li, Kaiyi
Bell, Diana
Mitani, Yoshitsugu
Marques-Piubelli, Mario L.
Cortez, Maria Angelica
Lin, Shiaw-Yih
Elamin, Yasir Y.
El-Naggar, Adel K.
Ferrarotto, Renata
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Cleveland Clin, Cleveland, OH USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6096
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Updated results of the Tide-A study evaluating avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients with metastatic renal cell carcinoma (mRCC).
    Arduini, Chiara
    Ciccarese, Chiara
    Acunzo, Alessandro
    Perrino, Matteo
    Maruzzo, Marco
    Verzoni, Elena
    Accettura, Caterina
    Bonomi, Lucia
    Buttigliero, Consuelo
    Cremante, Malvina
    Pipitone, Stefania
    Scartozzi, Mario
    Masini, Cristina
    Mollica, Veronica
    Primi, Francesca
    Strusi, Alessandro
    Buti, Sebastiano
    Zucali, Paolo Andrea
    Fantinel, Emanuela
    Iacovelli, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 551 - 551
  • [42] Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study
    Zhu, Guopei
    Zhang, Lin
    Dou, Shengjin
    Li, Rongrong
    Li, Jiang
    Ye, Lulu
    Jiang, Wen
    Dong, Minjun
    Ruan, Min
    Yang, Wenjun
    Zhang, Chenping
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [43] Local Control following Combination Hypofractionated Radiotherapy and Pembrolizumab in A Phase II Trial of Recurrent or Metastatic Adenoid Cystic Carcinoma Patients
    Bang, A.
    Mahmood, U.
    Chen, Y. H.
    Mak, R. H.
    Lorch, J.
    Hanna, G. J.
    Sridharan, V.
    Busse, P. M.
    Willers, H.
    Mamon, H. J.
    Yoo, H. J.
    Pai, S. I.
    Wirth, L.
    Haddad, R. I.
    Chau, N.
    Schoenfeld, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E363 - E363
  • [44] LOCAL CONTROL FOLLOWING COMBINATION HYPOFRACTIONATED RADIOTHERAPY AND PEMBROLIZUMAB IN A PHASE II TRIAL OF RECURRENT OR METASTATIC ADENOID CYSTIC CARCINOMA PATIENTS
    Bang, Andrew
    Mahmood, Umair
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Sridharan, Vishwajith
    Busse, Paul M.
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara I.
    Wirth, Lori J.
    Haddad, Robert I.
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S26 - S27
  • [45] Phase II study of nivolumab and ipilimumab for treatment of metastatic/recurrent adenoid cystic carcinoma (ACC) of all anatomic sites of origin and other malignant salivary gland tumors
    Chae, Young Kwang
    Duan, Richard
    Chung, Liam Il-Young
    Oh, Youjin
    Matsangou, Maria
    Agulnik, Mark
    Villaflor, Victoria
    Mahalingam, Devalingam
    CANCER RESEARCH, 2023, 83 (08)
  • [46] ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort
    Ho, A. L.
    Bowles, D. W.
    Even, C.
    Hao, D.
    Kang, H.
    Metcalf, R.
    Muzaffar, J.
    Oliva, M.
    Perez, C. A.
    Popovtzer, A.
    Rodriguez, C. P.
    Stemmer, S. M.
    Van Herpen, C. M.
    Winquist, E.
    Wirth, L. J.
    Worden, F. P.
    Xia, B.
    Gordon, G.
    Gordon, G. B.
    Ferrarotto, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S803 - S804
  • [47] Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Chow, Laura Quan Man
    Mehra, Ranee
    Haddad, Robert I.
    Mahipal, Amit
    Weiss, Jared
    Berger, Raanan
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Le, Dung T.
    Muro, Kei
    Geva, Ravit
    Chung, Hyun Cheol
    Lin, Chia-Chi
    Ayers, Mark
    Aurora-Garg, Deepti
    Lunceford, Jared K.
    Cheng, Jonathan D.
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): results from JAVELIN Renal 101
    Grimm, Marc-Oliver
    Oya, Mototsugu
    Choueiri, Toni K.
    Schmidinger, Manuela
    Quinn, David
    Gravis-Mescam, Gwenaelle
    Verzoni, Elena
    Van den Eertwegh, Alfonsus
    Di Pietro, Alessandra
    Mariani, Mariangela
    Wang, Jing
    Thomaidou, Despina
    Albiges, Laurence
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 100 - 100
  • [49] Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab plus axitinib (A plus Ax) or sunitinib (S): Results from JAVELIN Renal 101
    Grimm, M-O.
    Oya, M.
    Choueiri, T. K.
    Schmidinger, M.
    Quinn, D. I.
    Mescam, G. Gravis
    Verzoni, E.
    Van den Eertwegh, A. J. M.
    di Pietro, A.
    Mariani, M.
    Wang, J.
    Thomaidou, D.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S690 - S691
  • [50] Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study
    Iacovelli, R.
    Ciccarese, C.
    Bersanelli, M.
    Zucali, P. A.
    Fantinel, E.
    Bimbatti, D.
    Verzoni, E.
    Accettura, C.
    Bonomi, L.
    Buttigliero, C.
    Fornarini, G.
    Pipitone, S.
    Atzori, F.
    Masini, C.
    Massari, F.
    Primi, F.
    Buti, S.
    Perrino, M. R. A.
    Pafumi, S.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S1013 - S1013
12345